IGFBP: A Protein Involved in Cellular Growth and Development (P46214)

Target Name: Insulin-like growth factor-binding protein

NCBI ID: P46214

Insulin-like growth factor-binding protein

Other Name(s): IGFBP | GF-binding protein | IBP

IGFBP: A Protein Involved in Cellular Growth and Development

Insulin-like growth factor-binding protein (IGFBP), also known as nonspecific subtype (NSP), is a protein that plays a crucial role in cellular growth and development. It is a member of the insulin-like growth factor (IGF) family, which includes several proteins that are involved in the regulation of cell growth and differentiation. IGFBP is a 21-kDa protein that is expressed in a variety of tissues, including muscle, bone, and organs.

One of the unique features of IGFBP is its ability to interact with the insulin receptor, which is a protein that is involved in the regulation of glucose metabolism. This interaction between IGFBP and the insulin receptor allows IGFBP to regulate cellular growth and differentiation, including the growth and development of tissues.

IGFBP has been shown to play a role in several important cellular processes, including cell growth, apoptosis (programmed cell death), angiogenesis (the formation of new blood vessels), and plasticity (the ability of cells to change and adapt). It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway (transforming growth factor-尾 pathway), which is involved in cell growth, differentiation, and inflammation.

One of the potential drug targets for IGFBP is the use of inhibitors of the insulin receptor to prevent or reverse IGFBP-mediated signaling pathways. This can include inhibitors of the insulin receptor itself, such as those used in the treatment of type 2 diabetes, or inhibitors of IGFBP itself, such as those used in the treatment of cancer.

Another potential drug target for IGFBP is the use of small molecules that can modulate the activity of IGFBP. This can include inhibitors of IGFBP-interactive proteins, such as the transcription factor SMAD (small molecule-activated nuclear factor), which is involved in the regulation of cellular growth and differentiation.

IGFBP is also a potential biomarker for several diseases, including cancer, obesity, and diabetes. Its levels are often elevated in tissues that are affected by these conditions, and it has been shown to play a role in the regulation of cellular processes that are associated with these diseases.

In conclusion, IGFBP is a protein that is involved in the regulation of cellular growth and development, including the regulation of the insulin receptor and the TGF-β pathway. It is a potential drug target for the treatment of a variety of conditions, including cancer, obesity, and diabetes. Further research is needed to fully understand the role of IGFBP in cellular processes and its potential as a drug target.

Protein Name: Insulin-like Growth Factor-binding Protein (nonspecified Subtype)

The "Insulin-like growth factor-binding protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Insulin-like growth factor-binding protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets